ChemMedChem · 2007 · 81 citations · 9 references
MedicineMedicinal ChemistryOncologyMolecular OncologyOncogenesStructure-activity RelationshipsDrug-receptor InteractionsEnzyme InhibitionLigand BindingMyc Family OncogenesMyc InhibitorsMyc OncogenesMyc-max DimerizationPyrimidine AnalogsPyrimidine AnaloguesSubstitution Pattern AnalysisTarget-ligand Interactions
c-Myc/Max Dimerization. The interaction between the oncoprotein c-Myc and its activation partner Max is considered to be a desirable target for cancer drug development. However, the interaction is mediated by large α-helical interfaces without obvious binding sites for small molecule inhibitors. This paper describes the identification of a substitution pattern for pyrazolopyrimidines which appears to be associated with activity against this challenging target.
9
Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain
A.R. Ferré-D′Amaré, George C. Prendergast, Edward B. Ziff et al. · Nature · 1993 · 758 citations
X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA
Satish K. Nair, S.K. Burley · Cell · 2003 · 552 citations · Full text
Low molecular weight inhibitors of Myc–Max interaction and function
Xiaoying Yin, Christine Giap, John S. Lazo et al. · Oncogene · 2003 · 430 citations